SWOG clinical trial number
SWOG-8931 (INT-0108) (EST-3189)

Comparison of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil (CAF) and a 16-Week Multi-Drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer

Closed
Phase
Published
Abbreviated Title
Comparison of Cyclophosphamide, Doxorubicin, and 5-Fluorouracil (CAF) and a 16-Week Multi-Drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer
Activated
07/15/1990
Closed
04/29/1993

Research committees

Breast Cancer

Publication Information Expand/Collapse

1998

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An intergroup study.

JH Fetting;R Gray;DL Fairclough;TJ Smith;KA Margolin;ML Citron;M Grove-Conrad;D Cella;K Pandya;N Robert;IC Henderson;CK Osborne;MD Abeloff Journal of Clinical Oncology 16(7):2382-2391

1995

CAF vs 16 week multidrug regimen as adjuvant therapy for receptor-negative, node-positive breast cancer: An Intergroup study.

J Fetting;R Gray;M Abeloff;B Fowble;T Smith;S Vail;G Durrani;L Eudey;J Henney;K Margolin;M Citron;C Osborn;C Henderson American Society of Clinical Oncology 14(#83):96

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012303

Shortstop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer who Achieve PCR After Neoadjuvant Chemotherapy with HER2 Blockade
Research Committee(s)
Breast Cancer
Activated
07/25/2025
Open
SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
30%
Open
Phase